Cookie consent

We use cookies to improve your experience on this website. By continuing to browse our site you agree to our use of cookies. Tell me more | Cookie preferences

Novartis, GlaxoSmithKline ink $20B deal

    Just Watched

    Novartis, GlaxoSmithKline ink $20B deal

Jim Boulden speaks to the CEO's of GSK and Novartis about why they've agreed to swap assets and combine business units.